Mediaboss Marketing

PRESS RELEASE

Biotest Group reports increase of EBIT

- EBIT up 13.5% at EUR 11.8 million

- Sales increased to EUR 118.7 million

- Management Board confirms guidance

Dreieich, 8 May 2013. In the first three months of financial year 2013 the Biotest Group was able to significantly increase sales again and achieve a new quarterly sales record. In the reporting period the Group generated revenues of EUR 118.7 million compared to EUR 107.7 million in the same quarter of the previous year. This represents an increase of 10.2 %.

Profitability also increased significantly. Earnings before interest and taxes (EBIT) increased in the reporting period by 13.5 % from EUR 10.4 million to EUR 11.8 million. The largest increase was generated by the Plasma & Services segment, where EBIT increased by 83.3 % compared to the first quarter of 2012.

The growth in sales was driven primarily by the international markets. Whereas there was slight growth in Europe, sales in the US increased significantly. The market launch of Bivigam(R) in February 2013 was the main reason for the double-digit growth in this market.

The marketing authorisation of Bivigam(R) by the US Food and Drug Administration (FDA) as well as the market launch of the product represent important milestones for Biotest. The Biotest Group estimates a sales potential of about USD 100 million over the medium to long term for this immunoglobulin used to treat patients with primary humoral immune deficiencies.

The business performance of the Biotest Group continues to be very positive. For this reason the Management Board reaffirms its target of increasing sales by 10 % to 15 % in the current year. The management expects a similar increase in EBIT.

See the original post:
DGAP-News: Biotest AG: Biotest Group reports increase of EBIT